Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine M Kelly

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Cancer Management and Research|October 22, 2013
Benefit risk assessment and update on the use of docetaxel in the management of breast cancerScheryll Alken, Catherine M Kelly
Expert Opinion on Pharmacotherapy|January 8, 2010
Aromatase inhibitors alone or in sequence with tamoxifen - clinical evaluation of the BIG 1-98 trialCatherine M Kelly, Aman U Buzdar
Drugs|April 23, 2013
Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancerCatherine M Kelly, Aman U Buzdar
Expert Opinion on Pharmacotherapy|October 26, 2012
Vemurafenib for the treatment of melanomaEmmet John Jordan, Catherine M Kelly
Surgical Oncology Clinics of North America|July 13, 2010
Adjuvant chemotherapy in early-stage breast cancer: what, when, and for whom?Catherine M Kelly, Gabriel N Hortobagyi
The Lancet. Oncology|January 24, 2012
Aromatase inhibitors in premenopausal breast cancerCatherine M Kelly, Aman U Buzdar
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learnedCatherine M Kelly, Kathleen I Pritchard
Cancer Management and Research|August 24, 2022
Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical InsightsMairi W Lucas, Catherine M Kelly
Expert Opinion on Drug Safety|October 7, 2010
AnastrozoleCatherine M Kelly, Aman U Buzdar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Personalized medicine: what exactly is it and can we truly measure it?Catherine M Kelly, Kathleen I Pritchard
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Cancer Management and Research|October 22, 2013
Benefit risk assessment and update on the use of docetaxel in the management of breast cancerScheryll Alken, Catherine M Kelly
Expert Opinion on Pharmacotherapy|January 8, 2010
Aromatase inhibitors alone or in sequence with tamoxifen - clinical evaluation of the BIG 1-98 trialCatherine M Kelly, Aman U Buzdar
Drugs|April 23, 2013
Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancerCatherine M Kelly, Aman U Buzdar
Expert Opinion on Pharmacotherapy|October 26, 2012
Vemurafenib for the treatment of melanomaEmmet John Jordan, Catherine M Kelly
Surgical Oncology Clinics of North America|July 13, 2010
Adjuvant chemotherapy in early-stage breast cancer: what, when, and for whom?Catherine M Kelly, Gabriel N Hortobagyi
The Lancet. Oncology|January 24, 2012
Aromatase inhibitors in premenopausal breast cancerCatherine M Kelly, Aman U Buzdar
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learnedCatherine M Kelly, Kathleen I Pritchard
Cancer Management and Research|August 24, 2022
Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical InsightsMairi W Lucas, Catherine M Kelly
Expert Opinion on Drug Safety|October 7, 2010
AnastrozoleCatherine M Kelly, Aman U Buzdar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Personalized medicine: what exactly is it and can we truly measure it?Catherine M Kelly, Kathleen I Pritchard
Pageof 7